Agilent Beats On Q4 Earnings, Issues Mixed Guidance

Agilent Technologies Inc's A Q4 revenues rose 11% Y/Y to $1.85 billion, beating the analysts' average estimate of $1.76 billion.
By segment, the Life Sciences and Applied Markets group's revenues increased 16% Y/Y, or 22% on a core basis, to $1.12 billion, while the Agilent CrossLab group's revenues were up 7% (14% core) to $381 million.
The Diagnostics and Genomics Group's revenues grew 3% (8% core) to $352 million.
The company reported Q4 adjusted EPS of $1.53, beating the consensus Wall Street estimate of $1.39.
"Agilent had another excellent year, capping off 2022 with an outstanding fourth quarter," said Mike McMullen, Agilent president & CEO.
Guidance: For Q1 FY23, Agilent expects revenues of $1.68-$1.70 billion (consensus of $1.73 billion).
It sees adjusted EPS of $1.29-$1.31 vs. the consensus of $1.31.
Full-year fiscal 2023 revenues are anticipated to be $6.90-$7.00 billion, with adjusted EPS of $5.61-$5.69 compared to the consensus of $7.12 billion and $5.43, respectively.
Price Action: A shares closed 0.72% lower at $145.14 on Monday.

Earnings Calendar